Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Budesonide · Pulmicort Flexhaler, Pulmicort Respules

Small molecule · Agonist of glucocorticoid receptor (NR3C1) · developed by Astrazeneca

Approved FDA, Jun 1997
1 Registered trials

What is Budesonide?

Budesonide is an anti-inflammatory corticosteroid with high glucocorticoid and weak mineralocorticoid activity, binding glucocorticoid receptors with about 200-fold the affinity of cortisol. It is studied in ulcerative colitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Pulmicort Flexhaler, Pulmicort Respules, Uceris, MAP-0010, NSC-757788
Drug type
Small molecule
Targets
glucocorticoid receptor (NR3C1)
Mechanism
Agonist of glucocorticoid receptor (NR3C1)
Pathways
glucocorticoid receptor signaling, anti-inflammatory response
Therapy area
Gastroenterology
Developer
Astrazeneca
In trials of
BHC
FDA status
Approved as Pulmicort Flexhaler, Pulmicort Respules, Uceris (June 24, 1997), NDA020441 · FDA label
UNII
Q3OKS62Q6X

✅ FDA-approved uses

From the indications section of the FDA label (version of Jan 15, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05976802 Phase 4 Ulcerative Colitis Not yet recruiting BHC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ulcerative Colitis

Other drugs acting on NR3C1

Beclomethasone Dipropionate FDA approved IDP-118 FDA approved Infacort FDA approved Methylprednisolone FDA approved Mifepristone FDA approved Mometasone FDA approved Mometasone Furoate FDA approved Relacorilant FDA approved Chronocort Phase 3 Exicorilant Phase 1/2 Miricorilant Phase 2 ORIC-101 Phase 1

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.